Neuropore Therapies
Neuropore Therapies is a San Diego-based biopharmaceutical company dedicated to discovering and developing novel therapeutics for neurodegenerative disorders such as Parkinson's and Alzheimer's diseases. Their approach targets the core pathological processes, including toxic protein aggregation and neuroinflammation, with the aim of slowing disease progression and improving symptoms. They collaborate with academic institutions, foundations, and pharmaceutical companies to advance their pipeline of small molecule therapeutics.
Industries
Nr. of Employees
small (1-50)
Neuropore Therapies
Patents
Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways
US-12049462-B2
View DetailsTri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways
US-11492348-B2
View Details
Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways
US-12049462-B2
View DetailsTri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways
US-11492348-B2
View DetailsProducts
Clinical-stage small molecule modulating neuroinflammation and reducing pathological protein burden
An orally bioavailable, brain-penetrant small molecule developed to attenuate microglial and astrocytic activation, reduce misfolded protein burden and improve motor/functional endpoints in preclinical models; progressed through Phase 1 safety and PK studies in healthy volunteers.
Alpha-synuclein misfolding/oligomerization inhibitor advanced via partner collaboration
A brain-penetrant small molecule series designed to prevent misfolding and oligomerization of alpha-synuclein, discovered through structure-based approaches and advanced into clinical development through a partner-led program.
Clinical-stage small molecule modulating neuroinflammation and reducing pathological protein burden
An orally bioavailable, brain-penetrant small molecule developed to attenuate microglial and astrocytic activation, reduce misfolded protein burden and improve motor/functional endpoints in preclinical models; progressed through Phase 1 safety and PK studies in healthy volunteers.
Alpha-synuclein misfolding/oligomerization inhibitor advanced via partner collaboration
A brain-penetrant small molecule series designed to prevent misfolding and oligomerization of alpha-synuclein, discovered through structure-based approaches and advanced into clinical development through a partner-led program.
Services
Partnership-based evaluation and experimental validation of molecular targets identified by AI platforms, followed by small-molecule screening and lead optimization.
Negotiation and execution of licensing agreements for mechanistically distinct classes of brain-penetrant autophagy modulators to external partners.
Partnership-based evaluation and experimental validation of molecular targets identified by AI platforms, followed by small-molecule screening and lead optimization.
Negotiation and execution of licensing agreements for mechanistically distinct classes of brain-penetrant autophagy modulators to external partners.
Expertise Areas
- Small-molecule drug discovery for neurodegenerative diseases
- Structure-based drug design and molecular modeling
- Preclinical in vivo pharmacology and behavioral assessment
- Translational biomarker development (retinal imaging and blood biomarkers)
Key Technologies
- Structure-based drug design
- Dynamic molecular modeling
- Medicinal chemistry for BBB penetration
- Transgenic animal models
News & Updates
March 10-11, 2020, Tokyo, Japan
January 13-16, 2020, San Francisco, CA
November 11-13, 2019, Hamburg, Germany
June 3rd-6th, 2019, Philadelphia, PA USA
April 18th, 2019, Boston, MA USA
March 10-11, 2020, Tokyo, Japan
January 13-16, 2020, San Francisco, CA
November 11-13, 2019, Hamburg, Germany
June 3rd-6th, 2019, Philadelphia, PA USA
April 18th, 2019, Boston, MA USA